Introduction
While ProQR’s (PRQR) share price experienced an unpredicted run in 2018, it has now been back to the previous level. ProQR is a small company that focuses on developing drugs for a small number of patients with rare diseases. For example, it offers unique solutions for patients with inherited retinal diseases. However, the trial data of Sepofarsen (Phase 2/3 most developed candidate) might be delayed until 2022 due to the impact of Covid-19.
Despite this, ProQR can still be a very interesting candidate to add to your watchlist. Hence, it is necessary